Autorizzazione alla conduzione dello Studio: “Myulticenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lynphoma (DLBCL) patients.
Codice: FIL-GALILEO. Numero EudraCT: 2015-005273-20